The viral load or quantity of SARS-CoV-2 in the nasal cavity does not predict disease severity, according to a recent JAMA Network Open study.
The findings contradict those of earlier studies that found that patients with severe COVID-19 presentations tended to have a high viral load.
“The findings of this study suggest that caution should be exercised in the use of individual-level viral load … as a surrogate for COVID-19 severity, especially given increasing diversity in preexisting immunity,” the authors added.
Disease Severity Depends on Individual Immunity
Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center who was not involved in the study, said he was not too surprised at the findings. He added that COVID pneumonia, a complication associated with severe COVID-19, is known to be determined by the body’s immune response and less so by viral load.“It’s our immune response that determines [disease] severity. So the vigor of our immune response is largely associated with the pneumonia that occurs,” Dr. Schaffner said.
SARS-CoV-2 infects the body in two phases. The first is when the virus attaches to the cells in the nasal cavity and the upper respiratory tract. Symptoms tend to be mild at this stage.
In the second phase, the virus reaches the lower respiratory tract and can start disseminating into the body.
Some people’s immune systems may mount a highly inflammatory response to the virus, which can transform into severe disease; others may have mild or asymptomatic disease.
Mucosal Vaccines Reconsidered
While the study showed that high exposure to the virus couldn’t guarantee severe disease, the findings do not suggest that people will not become infected.“Being in a crowded area or near to someone who is infected would increase the likelihood of becoming infected,” Dr. Stanley Perlman, a professor of microbiology and immunology at the University of Iowa, told The Epoch Times.
The authors said that the study’s findings are particularly relevant to the development of COVID-19 mucosal vaccines.
The study’s findings would primarily affect “evaluating mucosal vaccine efficacy, since viral load will not necessarily reflect effects on clinical disease,” said Dr. Perlman.
Dr. Schaffner said mucosal vaccines for COVID-19 may still be relevant.
“The mucosal vaccines are, in theory, designed to prevent that initial infection,” Dr. Schaffner said. “We could prevent [the virus from initiating infections in the cells] or reduce the likelihood that, even though you’re exposed, the virus could not get established in your body and put you at risk of more severe disease.”
